Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2021
(Exact name of registrant as specified in its charter)
Delaware 001-40797 26-0199180
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification Number)
900 Island Drive
Redwood City, California 94065
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 232-7200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Name of each exchange
on which registered
Common Stock, $0.00001 par value per share PRCT The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Item 2.02 Results of Operations and Financial Condition
On November 5, 2021, PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2021. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.
Exhibit No.Description
104Cover Page Interactive Data File, formatted in Inline XBRL.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 4, 2021
/s/ Alaleh Nouri
Alaleh Nouri
General Counsel and Secretary

PROCEPT BioRobotics Corp. Reports Third Quarter 2021 Financial Results and Provides 2021 Revenue Guidance

REDWOOD CITY, Calif., November 4, 2021 -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the quarter ended September 30, 2021.

Recent Highlights
Total revenue of $8.7 million for the third quarter of 2021, compared to $2.1 million in the prior year period
U.S. system revenue of $5.0 million for the third quarter of 2021, compared to $0.6 million in the prior year period
U.S. handpiece revenue of $2.2 million for the third quarter of 2021, compared to $0.5 million in the prior year period
International revenue of $1.3 million for the third quarter of 2021, compared to $1.0. million in the prior year period
Completed initial public offering, raising approximately $172.4 million in net proceeds
Announced new positive coverage policy from Cigna, effective September 15, 2021
Issued 2021 total revenue guidance range of $33.0 to $33.3 million

“We are very pleased with the results we delivered in the third quarter, which was capped off by the positive coverage policy announcement by Cigna in late September to expand Aquablation covered lives by an additional 16 million persons,” said Reza Zadno, Chief Executive Officer. “We are also proud of our successful completion of our IPO and are grateful for the support of the participating investors. The proceeds from the offering will enable us to further scale our business and invest in the commercial infrastructure to accelerate the adoption of Aquablation therapy to become the standard of care for BPH.”

Third Quarter 2021 Financial Results

Total Revenue was $8.7 million in the third quarter 2021, an increase from $2.1 million in the third quarter of 2020. The increase was primarily driven by system sales to new and existing hospital customers. U.S. system revenue was $5.0 million, compared to $0.6 million in the prior year period. As of September 30, 2021, the install base of Aquabeam Robotic Systems in the U.S. was 75 units. U.S. handpiece and consumable revenue was $2.2 million, compared to $0.5 million in the third quarter of 2020. International revenue for the third quarter was $1.3 million, compared to $1.0 million in the third quarter of 2020.

Gross margin for the third quarter 2021 was 48.9% compared to a -1% in the third quarter of 2020 and 42.2% in the second quarter of 2021. The increase relative to the second quarter of 2021 was driven primarily by increased system average selling prices.
Total operating expenses in the third quarter of 2021 were $17.0 million, compared with $10.9 million in the prior year period. The increase was primarily driven by increased sales and marketing expenses to expand the sales organization and increased G&A expenses associated with being a public company.
Net loss was $14.1 million for the third quarter of 2021 compared to $12.0 million in the prior year period.
Cash and short-term investments as of September 30, 2021, totaled $320.5 million, while long-term borrowings totaled $50.0 million. The company received approximately $172.4 million of net proceeds from the initial public offering, which closed on September 17.

2021 Financial Guidance

The Company expects full year 2021 revenue to be in the range of $33.0 to $33.3 million.

Webcast and Conference Call Information
PROCEPT BioRobotics will host a conference call to discuss the third quarter 2021 financial results after the market close on Thursday, November 4th, 2021 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (800) 306-0005 for domestic callers or (209) 950-5968 for international callers, using conference ID: 7198987. Live audio of the webcast will be available on the “Investors” section of the company’s website at: The webcast will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Forward Looking Statements
This release contains forward‐looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Aquablation® therapy performed using PROCEPT’s products, including AquaBeam® Robotic System, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements may include information the impact of the COVID-19 pandemic on the Company and its operations, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margin, profitability, operating expenses, installed base growth, guidance for 2021 full year, commercial momentum, or overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on PROCEPT’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in PROCEPT’s filings with the Securities and Exchange Commission (the “SEC”), including PROCEPT’s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on September 16, 2021. PROCEPT does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT’s views as of any date subsequent to the date of this press release.

Investor Contact:
Gilmartin Group
Matt Bacso, CFA

PROCEPT BioRobotics Corporation
(in thousands)
September 30, 2021December 31, 2020
Current assets:
Cash and cash equivalents$320,484 $100,130 
Accounts receivable, net6,353 1,549 
Inventory10,401 6,924 
Prepaid expenses and other current assets2,232 1,653 
Total current assets339,470 110,256 
Restricted cash777 777 
Property and equipment, net5,731 8,274 
Operating lease right-of-use assets, net3,667 4,641 
Intangible assets, net1,818 2,023 
Total assets$351,463 $125,971 
Liabilities, Redeemable Convertible Preferred Stock and
Stockholders' Equity (Deficit)
Current liabilities:
Accounts payable$3,590 $1,240 
Accrued compensation4,875 4,640 
Note payable – current portion— 4,551 
Operating lease – current portion2,032 1,708 
Deferred revenue848 233 
Other current liabilities2,834 2,154 
Total current liabilities14,179 14,526 
Note payable – non-current portion49,762 44,407 
Operating lease – non-current portion2,550 4,096 
Loan facility derivative liability1,460 1,782 
Other non-current liabilities200 200 
Total liabilities68,151 65,011 
Redeemable convertible preferred stock243,854
Stockholders’ equity (deficit):
Common Stock and additional paid-in capital526,526 18,788 
Accumulated other comprehensive loss(41)(14)
Accumulated deficit(243,173)(201,668)
Total stockholders’ equity (deficit)283,312 (182,894)
Total liabilities, convertible redeemable preferred stock and stockholders’ equity (deficit)
$351,463 $125,971 

PROCEPT BioRobotics Corporation
(in thousands, except per share data)

Three Months Ended
September 30,
Nine Months Ended
September 30,
Revenue$8,668 $2,107 $24,335 $4,496 
Cost of sales4,428 2,138 12,986 6,221 
Gross profit4,240 (31)11,349 (1,725)
Operating expenses:
Research and development4,919 3,893 13,917 11,732 
Selling, general and administrative12,118 7,054 34,765 21,138 
Total operating expenses17,037 10,947 48,682 32,870 
Loss from operations(12,797)(10,978)(37,333)(34,595)
Interest expense(1,469)(1,387)(4,370)(3,490)
Interest and other income, net163 357 198 344 
Net loss$(14,103)$(12,008)$(41,505)$(37,741)
Net loss per share, basic and diluted$(1.22)$(2.77)$(5.64)$(11.34)
Weighted-average common shares used to
compute net loss per share attributable to
common shareholders, basic and diluted11,580 4,329 7,361 3,327 
Other comprehensive loss:
Unrealized (loss) gain on cash equivalents(2)(16)(27)
Comprehensive loss$(14,105)$(12,024)$(41,532)$(37,738)

PROCEPT BioRobotics Corporation
(in thousands)

Three Months Ended
September 30,
Nine Months Ended
September 30,
System sales and rentals$5,038 $646 $14,368 $1,106 
Hand pieces and other consumables2,184 451 5,458 930 
Service169 16 378 26 
Total U.S. revenue7,391 1,113 20,204 2,062 
Outside of U.S.
System sales and rentals481 369 1,725 1,111 
Hand pieces and other consumables666 596 2,159 1,278 
Service130 29 247 45 
Total outside of U.S. revenue1,277 994 4,131 2,434 
Total revenue$8,668 $2,107 $24,335 $4,496